Larsson, AM., Bendahl, PO., Aaltonen, K., Jansson S., Forsare C., Bergqvist M., Tykjaer Jorgensen C., Ryden L. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. Sci Rep 10, 4484 (2020). https://doi.org/10.1038/s41598-020-61416-1
McCartney A, Bonechi M, De Luca F, Biagioni C, Curigliano G, Moretti E, Minisini AM, Bergqvist M, Benelli M, Migliaccio I, Galardi F, Risi E, De Santo I, Romagnoli D, Biganzoli L, Di Leo A, Malorni L. Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. Clin Cancer Res. 2020 May 1;26(9):2131-2139. doi: 10.1158/1078-0432.CCR-19-3271. Epub 2020 Jan 14. PMID: 31937617.
McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart M, Gradishar WJ, Chia S, Di Leo A, Malorni L. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). Eur J Cancer. 2019 Jun;114:55-66. doi: 10.1016/j.ejca.2019.04.002. Epub 2019 May 3. PMID: 31059974.
Cabel L, Rosenblum D, Lerebours F, Brain E, Loirat D, Bergqvist M, Cottu P, Donnadieu A, Bethune A, Kiavue N, Rodrigues M, Pierga JY, Tanguy ML, Bidard FC. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res. 2020 Sep 14;22(1):98. doi: 10.1186/s13058-020-01334-2. PMID: 32928264; PMCID: PMC7489000.
Bonechi M., Galardi F., Biagioni C., De Luca F., Bergqvist M., Neumüller M., Guarducci C., Boccalini G., Gabellini S., Migliaccio I., Di Leo A., Pestrin M., Malorni L. et al Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018; 9: 16389-16399 https://www.oncotarget.com/article/24700/text/
Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumüller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7. PMID: 29162134; PMCID: PMC5699111.
Knudsen ES, Shapiro GI, Keyomarsi K., Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers, DOI: 10.1200/EDBK_281085 American Society of Clinical Oncology Educational Book 40 (May 18, 2020) 115-126. https://ascopubs.org/doi/full/10.1200/EDBK_281085
McCartney, A., Malorni, L. Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors. Br J Cancer 123, 176–177 (2020). https://doi.org/10.1038/s41416-020-0858-y
McCartney, A., Malorni, L. Thymidine Kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance. Biomarkers In Med. Vol. 14, No. 7, Editorial. 7 May 2020. https://doi.org/10.2217/bmm-2020-0072